close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

248.69 -2.14 (-0.85%)
Delayed Quote Updated: 4:00 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Away ↗
These biotechs’ valuations are through the roof. 
Via The Motley Fool
News headline image
Will Moderna Soar on Nov. 6? ↗
Moderna shares have outperformed tech giants this year. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility ↗
Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size. 
Via The Motley Fool
News headline image
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid? ↗
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved. 
Via MarketBeat
S&P 500 Premarket Movers: Royal Caribbean, S&P Global Gain; Xylem, Sherwin-Williams Fall ↗
Via Chartmill
Topics Stocks
S&P 500 Gap-Down Stocks for Oct. 26, 2026 ↗
Via Chartmill
Topics Stocks
S&P 500 Premarket Movers: Gainers and Losers Before the Open ↗
Via Chartmill
Topics Stocks
News headline image
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. 
From Biotech Insider
Via GlobeNewswire
News headline image
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial ↗
Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The... 
Via MarketBeat
Topics Artificial Intelligence
Most Active S&P 500 Stocks for Oct. 23, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
Lost Money on Moderna, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 23.07% Share Price Drop
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip? ↗
The stock fell 17% in one trading session. 
Via The Motley Fool
News headline image
Did You Lose Money on Moderna, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 23.07% Share Price Decline
From Law Offices of Howard G. Smith
Via Business Wire
S&P 500 Premarket Movers: CCI and SBAC Lead Gainers, TYL and DECK Top Decliners ↗
Via Chartmill
Topics Stocks
News headline image
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports ↗
Personalized cancer vaccine material allegedly circulated online ahead of formal Phase 3 results, today, Oct. 22, 2026. 
Via The Motley Fool
Topics Stocks
News headline image
Why Moderna (MRNA) stock is trading lower today
What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its per... 
Via StockStory
Topics Government
News headline image
Lost Money on Moderna, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 23.07% Stock Decline
From The Law Offices of Frank R. Cruz
Via Business Wire
S&P 500 Top Movers: Gainers and Losers for Oct. 22, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
From Merck & Co., Inc.
Via Business Wire
Most Active S&P 500 Stocks on Oct. 22: Netflix, Super Micro, Moderna ↗
Via Chartmill
Topics Stocks
News headline image
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 ↗
The market has rewarded this biotech for its breakthroughs. 
Via The Motley Fool
News headline image
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice ↗
This company made headlines with its coronavirus vaccine. 
Via The Motley Fool
News headline image
2 Large-Cap Stocks to Research Further and 1 That Underwhelm
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall ↗
Via Chartmill
Topics Stocks
S&P 500 Top Movers: Oct. 19, 2026 US Session Gainers and Losers ↗
Via Chartmill
Topics Stocks
Most Active S&P 500 Stocks on Oct. 19 ↗
Via Chartmill
Topics Stocks
News headline image
Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midter... 
Via StockStory
Topics Bonds Government
News headline image
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning ↗
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound. 
Via MarketBeat
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.